198 related articles for article (PubMed ID: 3318705)
21. [Antitumor activity and toxicity of KB-5424 R, a newly developed antitumor platinum compound].
Yamaguchi H; Kubota T; Takahara T; Takeuchi T; Furukawa T; Kase S; Josui K; Kodaira S; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1135-41. PubMed ID: 2053772
[TBL] [Abstract][Full Text] [Related]
22. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
23. Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice.
Lee K; O'Donnell RW; Marquis D; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):32-42. PubMed ID: 3286824
[TBL] [Abstract][Full Text] [Related]
24. Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.
Schroyens W; Dodion P; Rozencweig M
J Cancer Res Clin Oncol; 1990; 116(4):392-6. PubMed ID: 2202731
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of cisplatin analogs against malignant ovarian tumor xenografts into nude mice.
Hamaguchi K; Miyahara K; Nishimura H; Tashiro M; Kishi N; Matsumura T; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1755-9. PubMed ID: 3069943
[TBL] [Abstract][Full Text] [Related]
26. [Organoplatinum compounds. 1987 update].
Extra JM; Espie M; Calvo F; Marty M
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):123-30. PubMed ID: 3290835
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts.
Erlichman C; Vidgen D; Wu A
J Natl Cancer Inst; 1985 Sep; 75(3):499-505. PubMed ID: 3897683
[TBL] [Abstract][Full Text] [Related]
28. [Experimental study on the anti-tumor effects of CDDP derivatives on head and neck squamous cell carcinoma cell lines].
Tsukuda M; Yoshida T; Kubota A; Yanoma S; Watanabe S; Takahashi K; Ono T; Sawaki S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2811-4. PubMed ID: 3415274
[No Abstract] [Full Text] [Related]
29. The relationship between tumor size and chemosensitivity of murine bladder cancer.
Lee KE; Fujioka T; Kubota T; Hoffman R
Anticancer Res; 1994; 14(2A):465-8. PubMed ID: 8017849
[TBL] [Abstract][Full Text] [Related]
30. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
31. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Müller LJ; Moorer-van Delft CM; Roubos EW; Vermorken JB; Boer HH
Cancer Res; 1992 Feb; 52(4):963-73. PubMed ID: 1737358
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effect of CDDP and VP-16 against human bladder cancers.
Gotoh A; Mizuno Y; Okada H; Arakawa S; Kitazawa S; Maeda S; Kamidono S
In Vivo; 1995; 9(3):263-7. PubMed ID: 8562894
[TBL] [Abstract][Full Text] [Related]
33. Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice.
Hoshiya Y; Kubota T; Matsuzaki SW; Kitajima M; Hoffman RM
Anticancer Res; 1996; 16(6B):3515-7. PubMed ID: 9042214
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of a new platinum complex, 2-aminomethyl-pyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II).
Endoh K; Akamatsu K; Matsumoto T; Morikawa K; Honda M; Mitsui H; Koizumi M; Koizumi K; Matsuno T
Anticancer Res; 1989; 9(4):987-91. PubMed ID: 2817826
[TBL] [Abstract][Full Text] [Related]
35. [Results of drug sensitivity test of UFT, doxorubicin and cisplatin using human urogenital cancers transplanted subcutaneously into nude mice].
Murahashi I; Hosoya Y; Mukae K; Honda M; Takasaki E
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3059-65. PubMed ID: 3142366
[TBL] [Abstract][Full Text] [Related]
36. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
37. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Cheung YW; Cradock JC; Vishnuvajjala BR; Flora KP
Am J Hosp Pharm; 1987 Jan; 44(1):124-30. PubMed ID: 3548341
[TBL] [Abstract][Full Text] [Related]
38. Whither carboplatin? A replacement for or an alternative to cisplatin?
Gil A
J Clin Oncol; 1987 Dec; 5(12):2041-2. PubMed ID: 3316520
[No Abstract] [Full Text] [Related]
39. Efficacy of new platinum analog DPPE in an orthotopic nude mouse model of human colon cancer.
Rho YS; Lee KT; Jung JC; Yoon C; An Z; Hoffman RM; Chang SG
Anticancer Res; 1999; 19(1A):157-61. PubMed ID: 10226537
[TBL] [Abstract][Full Text] [Related]
40. Bladder cancer xenografts: a model of tumor cell heterogeneity.
Russell PJ; Raghavan D; Gregory P; Philips J; Wills EJ; Jelbart M; Wass J; Zbroja RA; Vincent PC
Cancer Res; 1986 Apr; 46(4 Pt 2):2035-40. PubMed ID: 2418959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
